Non-functioning pituitary adenomas

Best Practice and Research: Clinical Endocrinology and Metabolism

Volumn 23, Issue 5, 2009, Pages 625-638

  Greenman, Yona ^a   Stern, Naftali ^a  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

gonadotroph; non functioning; pituitary adenoma

Indexed keywords

CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; GONADOTROPIN; OCTREOTIDE; SOMATOSTATIN DERIVATIVE;

CLINICAL FEATURE; CLINICAL OBSERVATION; COMPUTER ASSISTED TOMOGRAPHY; CRANIOPHARYNGIOMA; DIFFERENTIAL DIAGNOSIS; DRUG MECHANISM; DRUG MEGADOSE; EVIDENCE BASED MEDICINE; FOLLOW UP; GONADOTROPIN RELEASE; GONADOTROPIN SECRETING CELL; HEADACHE; HUMAN; HYPERPROLACTINEMIA; HYPOPHYSIS FUNCTION; HYPOPITUITARISM; NONFUNCTIONING PITUITARY ADENOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; POSTOPERATIVE CARE; POSTOPERATIVE COMPLICATION; QUALITY OF LIFE; REVIEW; SEX DIFFERENCE; TRANSSPHENOIDAL HYPOPHYSECTOMY; TUMOR CLASSIFICATION; TUMOR GROWTH; VISUAL DISORDER; VISUAL FIELD DEFECT; WATCHFUL WAITING;

ADENOMA; GONADOTROPINS, PITUITARY; HUMANS; HYPOPITUITARISM; NEUROSURGICAL PROCEDURES; PITUITARY NEOPLASMS;

EID: 71849119505     PISSN: 1521690X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beem.2009.05.005     Document Type: Review

References (104)

1. Kwekkeboom D.J., de Jong F.H., and Lamberts S.W. Gonadotropin release by clinically nonfunctioning and gonadotroph pituitary adenomas in vivo and in vitro: relation to sex and effects of thyrotropin-releasing hormone, gonadotropin-releasing hormone, and bromocriptine. J Clin Endocrinol Metab 68 (1989) 1128-1135
2. Ezzat S., Asa S.L., Couldwell W.T., et al. The prevalence of pituitary adenomas. A systematic review. Cancer 101 (2004) 613-619
3. Buurman H., and Saeger W. Subclinical adenomas in postmortem pituitaries: classification and correlations to clinical data. European Journal of Endocrinology 154 (2006) 753-756
4. Davis J.R.E., Farrel W.E., and Clayton R.N. Pituitary tumors. Reproduction 121 (2001) 363-371
5. Daly A.F., Rixhon M., Adam C., et al. High prevalence of pituitary adenomas: a cross-sectional study in the province of Liège, Belgium. Journal of Clinical Endocrinology and Metabolism 91 (2006) 4769-4775
6. Saeger W., Lüdecke D.K., Buchfelder M., et al. Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry. European Journal of Endocrinology 156 (2007) 203-216
7. Yamada S., Ohyama K., Taguchi M., et al. A study of the correlation between morphological findings and biological activities in clinically nonfunctioning pituitary adenomas. Neurosurgery 61 (2007) 580-585
8. Al-Shraim M., and Asa S.L. The 2004 World Health Organization classification of pituitary tumors: what is new?. Acta Neuropathologica 111 (2006) 1-7
9. Asa S.L., Cheng Z., Ramyar L., et al. Human pituitary null cell adenomas and oncocytomas in vitro: effects of adenohypophysiotropic hormones and gonadal steroids on hormone secretion and tumor cell morphology. The Journal of Clinical Endocrinology and Metabolism 74 (1992) 1128-1134
10. Ingraham H.A., Chen R., Mangalam H.J., et al. A tissue specific transcription factor containing a homeodomain specifies a pituitary phenotype. Cell 55 (1988) 519-529
11. Lamolet B., Pulichino A.M., Lamonerie T., et al. A pituitary cell restricted T box factor, Tpit, activates POMC transcription in cooperation with Pitx homeoproteins. Cell 104 (2001) 849-859
12. Asa S.L. Practical pituitary pathology. What does the pathologist need to know?. Archives of Pathology and Laboratory Medicine 132 (2008) 1231-1240
13. Bradley K.J., Wass J.A., and Turner H.E. Non-functioning pituitary adenomas with positive immunoreactivity for ACTH behave more aggressively than ACTH immunonegative tumors but do not recur more frequently. Clinical Endocrinology 58 (2003) 59-64
14. Horvath E., Kovacs K., Smyth H.S., et al. A novel type of pituitary adenoma: morphological features and clinical correlations. The Journal of Clinical Endocrinology and Metabolism 66 (1988) 1111-1118
15. Nomikos P., Ladar C., Fahlbusch R., et al. Impact of primary surgery on pituitary function in patients with non-functioning pituitary adenomas - a study on 721 patients. Acta Neurochirurgica 146 (2004) 27-35
16. Losa M., Mortini P., Barzaghi R., et al. Early results of surgery in patients with nonfunctioning pituitary adenomas and analysis of the risk of tumor recurrence. Journal of Neurosurgery 108 (2008) 525-532
17. Chang E.F., Zada G., Kim S., et al. Long-term recurrence and mortality after surgery and adjuvant radiotherapy for nonfunctional pituitary adenomas. Journal of Neurosurgery 108 (2008) 736-745
18. Arafah B.M., Prunty D., Ybarra J., et al. The dominant role of increased intrasellar pressure in the pathogenesis of hypopituitarism, hyperprolactinemia, and headaches in patients with pituitary adenomas. The Journal of Clinical Endocrinology and Metabolism 85 (2000) 1789-1793
19. Greenman Y., Ouaknine G., Veshchev I., et al. Postoperative surveillance of clinically nonfunctioning pituitary macroadenomas: markers of tumour quiescence and regrowth. Clinical Endocrinology 58 (2003) 763-769
20. Kim S.H., Lee K.C., and Kim S.H. Cranial nerve palsies accompanying pituitary tumor. Journal of Clinical Neuroscience 14 (2007) 1158-1162
21. Deepak D., Daousi C., Javadpour M., et al. Macroprolactinomas and epilepsy. Clinical Endocrinology 66 (2007) 503-507
22. Carroll W.R., Cohen S., and Sullivan M.J. Spontaneous CSF rhinorrhea: an unusual presentation of a pituitary adenoma. Otolaryngology-Head and Neck Surgery 104 (1991) 380-383
23. Dekkers O.M., Pereira A.M., Roelfsema J.H.C., et al. Observation alone after transsphenoidal surgery for nonfunctioning pituitary macroadenoma. The Journal of Clinical Endocrinology and Metabolism 91 (2006) 1796-1801
24. Arafah B.M. Reversible hypopituitarism in patients with large nonfunctioning pituitary adenomas. The Journal of Clinical Endocrinology and Metabolism 62 (1986) 1173-1179
25. Greenman Y., Tordjman K., Kisch E., et al. Relative sparing of anterior pituitary function in patients with growth hormone-secreting macroadenomas: comparison with nonfunctioning macroadenomas. The Journal of Clinical Endocrinology and Metabolism 80 (1995) 1577-1583
26. Webb S.M., Rigla M., Wägner A., et al. Recovery of hypopituitarism after neurosurgical treatment of pituitary adenomas. The Journal of Clinical Endocrinology and Metabolism 84 (1999) 3696-3700
27. Young W.F., Scheithauer B.W., Kovacs K.T., et al. Gonadotroph adenoma of the pituitary gland: a clinicopathologic analysis of 100 cases. Mayo Clinic Proceedings 71 (1996) 649-656
28. Hanson P.L., Aylwin S.J.B., Monson J.P., et al. FSH secretion predominates in vivo and in vitro in patients with non-functioning pituitary adenomas. European Journal of Endocrinology 152 (2005) 363-370
29. Cooper O., Geller J.L., and Melmed S. Ovarian hyperstimulation syndrome caused by an FSH-secreting pituitary adenoma. Nature Clinical Practice. Endocrinology and Metabolism 4 (2008) 234-238
30. Snyder P.J., and Sterling F.H. Hypersecretion of LH and FSH by a pituitary adenoma. The Journal of Clinical Endocrinology and Metabolism 42 (1976) 544-550
31. Heseltine D., White M.C., Kendall-Taylor P., et al. Testicular enlargement and elevated serum inhibin concentrations occur in patients with pituitary macroadenomas secreting follicle stimulating hormone. Clinical Endocrinology 31 (1989) 411-423
32. Faggiano M., Criscuolo T., Perrone I., et al. Sexual precocity in a boy due to hypersecretion of LH and prolactin by a pituitary adenoma. Acta Endocrinologica 102 (1983) 167-172
33. Abrosi B., Bassetti M., Ferrario R., et al. Precocious puberty in a boy with a PRL-, LH- and FSH-secreting pituitary tumour: biosynthetic characterization and clinical studies. Acta Endocrinologica 122 (1990) 569-576
34. Daneshdoost L., Genarelli T.A., Bashey H.M., et al. Recognition of gonadotroph adenomas in women. The New England Journal of Medicine 324 (1991) 589-594
35. Somjen D., Tordjman K., Kohen F., et al. Combined βFSH and βLH response to TRH in patients with clinically non-functioning pituitary adenomas. Clinical Endocrinology 46 (1997) 555-562
36. Nobels F.R.E., Kwekkeboom D.J., Coopman W., et al. A comparison between the diagnostic value of gonadotropins, α-subunits, and chromogranin-A and their response to thyrotropin-releasing hormone in clinically nonfunctioning, α-subunit-secreting, and gonadotroph pituitary adenomas. The Journal of Clinical Endocrinology and Metabolism 77 (1993) 784-789
37. Yoshino A., Katayama Y., Watanabe T., et al. Apoplexy accompanying pituitary adenoma as a complication of preoperative anterior pituitary function tests. Acta Neurochirurgica 149 (2007) 557-565
38. Karavitaki N., Thanabalasingham G., Shore H.C.A., et al. Do the limits of serum prolactin in disconnection hyperprolactinaemia need re-definition? A study of 226 patients with histologically verified non-functioning pituitary macroadenoma. Clinical Endocrinology 65 (2006) 524-529
39. Naidich M.J., and Russel E.J. Current approaches to imaging of the sellar region and pituitary. Endocrinology and Metabolism Clinics of North America 28 (1999) 45-79
40. Rao V.J., James R.A., and Mitra D. Imaging characteristics of common suprasellar lesions with emphasis on MRI findings. Clinical Radiology 63 (2008) 939-947
41. Reincke M., Allolio B., Saeger J., et al. The "incidentaloma" of the pituitary gland. Is neurosurgery required?. JAMA 263 (1990) 2772-2776
42. Donovan L.E., and Corenblum B. The natural history of pituitary incidentaloma. Archives of Internal Medicine 155 (1995) 181-183
43. Sanno N., Oyama K., Tahara S., et al. A survey of pituitary incidentaloma in Japan. European Journal of Endocrinology 149 (2003) 123-127
44. Nishizawa S., Ohta S., Yokoyama T., et al. Therapeutic strategies for incidentally found pituitary tumors ("Pituitary Incidentalomas"). Neurosurgery 43 (1998) 1344-1348
45. Igarashi T., Saeki N., and Yamaura A. Long-term magnetic resonance imaging follow-up of asymptomatic sellar tumors - their natural history and surgical indications. Neurologia Medico-Chirurgica (Tokyo) 39 (1999) 592-599
46. Dekkers O.M., Hammer S., de Keizer R.J.W., et al. The natural course of non-functioning pituitary macroadenomas. European Journal of Endocrinology 156 (2007) 217-224
47. Arita K., Tominaga A., Sugiyama K., et al. Natural course of incidentally found nonfunctioning pituitary adenoma, with special reference to pituitary apoplexy during follow-up examination. Journal of Neurosurgery 104 (2006) 884-891
48. Feldkamp J., Santen R., Harms E., et al. Incidentally discovered pituitary lesions: high frequency of macroadenomas and hormone-secreting adenomas-results of a prospective study. Clinical Endocrinology 51 (1999) 109-113
49. Karavitaki N., Collison K., Halliday J., et al. What is the natural history of nonoperated nonfunctioning pituitary adenomas?. Clinical Endocrinology 67 (2007) 938-943
50. Black P.M., Zervas N.T., and Candia G. Management of large pituitary adenomas by transsphenoidal surgery. Surgical Neurology 29 (1988) 443-447
51. Ferrante E., Ferraroni M., Castrignano T., et al. Non-functioning pituitary adenoma database: a useful resource to improve the clinical management of pituitary tumors. European Journal of Endocrinology 155 (2006) 823-829
52. Zhang X., Fein Z., Zhang J., et al. Management of nonfunctioning pituitary adenomas with suprasellar extensions by transsphenoidal microsurgery. Surgical Neurology 52 (1999) 380-385
53. Park P., Chandler W., Barkan A., et al. The role of radiation therapy after surgical resection of nonfunctional pituitary macroadenomas. Neurosurgery 55 (2004) 100-106
54. Honneger J., Ernemann U., Psaras T., et al. Objective criteria for successful transsphenoidal removal of suprasellar nonfunctioning pituitary adenomas. A prospective study. Acta Neurochirurgica (Wien) 149 (2007) 21-29
55. Ciric I., Ragin A., Baumgartner C., et al. Complications of transsphenoidal surgery: results of a national survey, review of the literature and personal experience. Neurosurgery 40 (1997) 225-236
56. Barker F.G., Klibanski A., and Swearingen B. Transsphenoidal surgery for pituitary tumors in the United States, 1996-2000: mortality, morbidity, and the effects of hospital and surgeon volume. The Journal of Clinical Endocrinology and Metabolism 88 (2003) 4709-4719
57. Nemergut E.C., Zuo Z., Jane J.A., et al. Predictors of diabetes insipidus after transsphenoidal surgery: a review of 881 patients. Journal of Neurosurgery 103 (2005) 448-454
58. Comtois R., Beauregard H., Somma M., et al. The clinical and endocrine outcome to trans-sphenoidal microsurgery of nonsecreting pituitary adenomas. Cancer 68 (1991) 860-866
59. Kremmer P., Forsting M., Ranaei G., et al. Magnetic resonance imaging after transsphenoidal surgery of clinically nonfunctional pituitary macroadenomas and its impact on detecting residual adenoma. Acta Neurochirurgica(Wien) 144 (2002) 433-443
60. Turner H.E., Stratton I.M., Byrne J.V., et al. Audit of selected patients with nonfunctioning pituitary adenomas treated without irradiation - a follow-up study. Clinical Endocrinology 51 (1999) 281-284
61. Kontogeorgos G. Predictive markers of pituitary adenoma behavior. Neuroendocrinology 83 (2006) 179-188
62. Thapar K., Kovacs K., Scheithauer B., et al. Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-1 antibody. Neurosurgery 38 (1996) 99-107
63. Mastronardi L., Guiducci A., Spera C., et al. Ki-67 labelling index and invasiveness among anterior pituitary adenomas: analysis of 103 cases using the MIB-1 monoclonal antibody. Journal of Clinical Pathology 52 (1999) 107-111
64. Honegger J., Prettin C., Feuerhake F., et al. Expression of Ki-67 antigen in nonfunctioning pituitary adenomas: correlation with growth velocity and invasiveness. Journal of Neurosurgery 99 (2003) 674-679
65. Gejman R., Swearingen B., and Hedley-Whyte E.T. Role of Ki-67 proliferation index and p53 expression in predicting progression of pituitary adenomas. Human Pathology 38 (2008) 758-766
66. Losa M., Franzin A., Mangili F., et al. Proliferation index of nonfunctioning pituitary adenomas: correlations with clinical characteristics and long term follow-up studies. Neurosurgery 47 (2000) 1313-1319
67. Dubois S., Guyetant S., Menei P., et al. Relevance of Ki-67 and prognostic factors for recurrence/progression of gonadotropic adenomas after first surgery. European Journal of Endocrinology 157 (2007) 141-147
68. Gittoes N.J.L., Bates A.S., Tse W., et al. Radiotherapy for non-functioning pituitary tumours. Clinical Endocrinology 48 (1998) 331-337
69. Erfurth E.M., Bulow B., Svahn-Tapper G., et al. Risk factors for cerebrovascular deaths in patients operated and irradiated for pituitary tumors. The Journal of Clinical Endocrinology and Metabolism 87 (2002) 4892-4899
70. Minniti G., Traish D., Ashley S., et al. Risk of second brain tumor after conservative surgery and radiotherapy for pituitary adenomas; update after an additional 10 years. The Journal of Clinical Endocrinology and Metabolism 90 (2005) 800-804
71. Tomlinson J.W., Holden N., Hills R.K., et al. Association between premature mortality and hypopituitarism, West Midlands prospective hypopituitary study group. Lancet 357 (2001) 425-431
72. Tsang R.W., Brierley J.D., Panzarella T., et al. Radiation therapy for pituitary adenoma: treatment outcome and prognostic factors. International Journal of Radiation Oncology Biology Physics 30 (1994) 557-565
73. Sheehan J.P., Kondziolka D., Flickinger J., et al. Radiosurgery for residual or recurrent nonfunctioning pituitary adenoma. Journal of Neurosurgery 97 Suppl. 5 (2002) 408-414
74. Kanner A.A., Corn B.W., and Greenman Y. Radiotherapy of nonfunctioning and gonadotroph adenomas. Pituitary 12 (2009) 15-22
75. Minniti G., Jafrain-Rea M.L., Osti M., et al. Radiotherapy for nonfunctioning pituitary adenomas: from conventional to modern stereotactic radiation techniques. Neurosurgical Review 30 (2007) 167-176
76. Bevan J.S., and Burke C.W. Non-functioning pituitary adenomas do not regress during bromocriptine therapy but possess membrane-bound dopamine receptors which bind bromocriptine. Clinical Endocrinology 25 (1986) 561-572
77. Renner U., Arzberger T., Pagotto U., et al. Heterogeneous dopamine D2 receptor subtype messenger ribonucleic acid expression in clinically nonfunctioning pituitary adenomas. The Journal of Clinical Endocrinology and Metabolism 83 (1998) 1368-1375
78. Pivonello R., Matrone C., Filippela M., et al. Dopamine receptor expression and function in clinically nonfunctioning pituitary tumors: comparison with the effectiveness of cabergoline treatment. The Journal of Clinical Endocrinology and Metabolism 89 (2004) 1674-1683
79. Kwekkeboom D.J., Hofland L.J., van Koetsveld P.M., et al. Bromocriptine increasingly suppresses the in vitro gonadotropin and alpha-subunit release from pituitary adenomas during long term culture. The Journal of Clinical Endocrinology and Metabolism 71 (1990) 718-724
80. Kwekkeboom D.J., and Lamberts S.W. Lon-term treatment with the dopamine agonist CV 205-502 of patients with a clinically non-functioning, gonadotroph, or alpha-subunit secreting pituitary adenoma. Clinical Endocrinology 36 (1992) 171-176
81. Florio T., Barbieri F., Spaziante R., et al. Efficacy of a dopamine-somatostatin chimeric molecule, BIM-23A760, in the control of cell growth from primary cultures of human non-functioning pituitary adenomas: a multi-center study. Endocrine-related Cancer 15 (2008) 583-596
82. Colao A., Di Somma C., Pivonello R., et al. Medical therapy for clinically non-functioning pituitary adenomas. Endocrine-related Cancer 15 (2008) 905-915
83. Greenman Y., Tordjman K., Osher E., et al. Postoperative treatment of clinically nonfunctioning pituitary adenomas with dopamine agonists decreases tumour remnant growth. Clinical Endocrinology 63 (2005) 39-394
84. Zanettini R., Antonini A., Gatto G., et al. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. The New England Journal of Medicine 356 (2007) 39-46
85. Lancellotti P., Livadariu E., Markov M., et al. Cabergoline and the risk of valvular lesions in endocrine disease. European Journal of Endocrinology 159 (2008) 1-5
86. Greenman Y., and Melmed S. Expression of three somatostatin receptor subtypes in pituitary adenomas: evidence for preferential SSTR5 expression in the mammosomatotroph lineage. The Journal of Clinical Endocrinology and Metabolism 79 (1994) 724-729
87. Taboada G.F., Luque R.M., Bastos W., et al. Quantitative analysis of somatostatin receptor subtype (SSTR1-5) gene expression levels in somatotropinomas and non-functioning pituitary adenomas. European Journal of Endocrinology 156 (2007) 65-74
88. Pawlikowski M., Lawnicka H., Pisarek H., et al. Effects of somatostatin-14 and the receptor specific somatostatin analogs on chromogranin A and alpha-subunit (alpha-SU) release from "clinically nonfunctioning "pituitary adenoma cells incubated in vitro. Journal of Physiology and Pharmacology 58 (2007) 179-188
89. Florio T., Thellung S., Arena S., et al. Somatostatin and its analog lanreotide inhibit the proliferation of dispersed human non-functioning pituitary adenoma cells in vitro. European Journal of Endocrinology 141 (1999) 396-408
90. Zatelli M.C., Piccin D., Bottoni A., et al. Evidence for differential effects of selective somatostatin receptor subtype agonists on α-subunit and chromogranin-A secretion and on cell viability in human nonfunctioning pituitary adenomas in vitro. The Journal of Clinical Endocrinology and Metabolism 89 (2004) 5181-5188
91. Zatelli M.C., Piccin D., Vignalli C., et al. Pasireotide, a multiple somatostatin receptor subtypes ligand, reduces cell viability in non-functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretion. Endocrine-related Cancer 14 (2007) 91-102
92. Rocheville M., Lange D.C., Kumar U., et al. Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. Science 288 (2000) 154-157
93. Andersen M., Bjerre P., Henrik D., et al. In vivo secretory potential and the effect of combination therapy with octreotide and cabergoline in patients with clinically non-functioning pituitary adenomas. Clinical Endocrinology 54 (2001) 23-30
94. Dekkers O.M., van der Klaauw A.A., Pereira A.M., et al. Quality of life is decreased after treatment for nonfunctioning pituitary macroadenoma. The Journal of Clinical Endocrinology and Metabolism 91 (2006) 3364-3369
95. van der Klaauw A.A., Kars M., Biermasz N.R., et al. Disease-specific impairments in quality of life during long-term follow-up of patients with different pituitary adenomas. Clinical Endocrinology 69 (2008) 775-784
96. Page R.C., Hammersley M.S., Burke C.W., et al. An account of the quality of life of patients after treatment for non-functioning pituitary tumours. Clinical Endocrinology 46 (1997) 401-406
97. van Beek A.P., van den Bergh A.C.M., van den berg L.M., et al. Radiotherapy is not associated with reduced quality of life and cognitive function in patients treated for nonfunctioning pituitary adenoma. International Journal of Radiation Oncology Biology Physics 68 (2007) 986-991
98. Lindholm J., Nielsen H., Bjerre P., et al. Hypopituitarism and mortality in pituitary adenomas. Clinical Endocrinology 65 (2006) 51-58
99. Fainstein Day P., Guitelman M., Artese R., et al. Retrospective multicentric study of pituitary incidentalomas. Pituitary 7 (2004) 145-148
100. Lillehei K.O., Kirschman D.L., Kleinschmidt-DeMasters B.K., et al. Reassessment of the role of radiation therapy in the treatment of endocrine-inactive pituitary macroadenomas. Neurosurgery 43 (1998) 432-438
101. Woolons A.C., Hunn M.K., Rajapakse Y.R., et al. Nonfunctioning pituitary adenomas: indications for postoperative radiotherapy. Clinical Endocrinology 53 (2000) 713-717
102. Soto-Ares G., Cortet-Rudelli C., Assaker R., et al. MRI protocol technique in the optimal therapeutic strategy of non-functioning pituitary adenomas. European Journal of Endocrinology 146 (2002) 179-186
103. van den Bergh A.C.M., van den Bergh G., Schoorl M.A., et al. Immediate postoperative radiotherapy in residual nonfunctioning pituitary adenoma: beneficial effect on local control without additional negative impact on pituitary function and life expectancy. International Journal of Radiation Oncology Biology Physics 67 (2007) 863-869
104. O'Sullivan EP, Woods C, Glynn N, et-al. The natural history of surgically treated but radiotherapy naïve non-functioning pituitary adenomas. Clinical Endocrinology. doi:10.1111/j1365-2265.2009.03583.x.